SI SHOULDER INNOVATIONS, INC.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1699350 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY54.9%
TTM net income YoY8.3%
TTM EPS YoY102.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin77.8%
Operating margin-54.4%
Net margin-51.7%
FCF margin-66.2%
EBITDA margin-47.9%
Returns
ROE-25.1%
ROA-20.6%
ROIC (approx.)-27.1%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets18.6%
Debt / equity0.13x
Current ratio10.68x
Interest coverage15.44x
Cash quality & payout
Operating cash flow / net income1.05x
Accruals ratio1.0%
Payout ratio—
Capex / revenue12.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $47.32M | $31.62M |
| Cost of revenue | $11.12M | $7.28M |
| Gross profit | $36.20M | $24.34M |
| R&D expense | $7.73M | $4.49M |
| SG&A expense | $54.77M | $34.51M |
| Operating income | -$26.30M | -$14.65M |
| Interest expense | $70,000 | $1.32M |
| Pretax income | -$40.36M | -$15.62M |
| Income tax | $0 | $0 |
| Net income | -$40.36M | -$15.62M |
| EBITDA | -$23.39M | -$12.76M |
| EPS (basic) | -4.65 | -242.04 |
| EPS (diluted) | -4.65 | -242.04 |
| Weighted avg. shares (diluted) | 8.67M | 64,530 |
| Balance sheet | ||
| Cash & equivalents | $26.87M | $6.12M |
| Short-term investments | $97.43M | $8.92M |
| Receivables | $8.27M | $5.12M |
| Inventory | $21.59M | $13.96M |
| Current assets | $157.16M | $35.12M |
| PP&E, net | $12.53M | $7.49M |
| Intangibles | $100,000 | $400,000 |
| Total assets | $169.91M | $43.08M |
| Current liabilities | $14.20M | $7.65M |
| Long-term debt | $14.91M | $14.66M |
| Total debt | $14.91M | $14.66M |
| Total liabilities | $29.16M | $23.30M |
| Shareholders' equity | $140.75M | -$54.70M |
| Net debt | -$11.96M | $8.54M |
| Shares outstanding | 20.62M | 83,882 |
| Cash flow statement | ||
| Operating cash flow | -$28.61M | -$14.14M |
| Capital expenditure | $7.41M | $4.01M |
| Free cash flow | -$36.02M | -$18.16M |
| Investing cash flow | -$95.60M | $13.96M |
| Financing cash flow | $144.96M | $66,000 |
| Depreciation & amortization | $2.91M | $1.90M |
| Stock-based compensation | $996,000 | $754,000 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.